Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CC312 in moderate-to-severe SLE
NCT07177911Phase 1Recruiting
- Sponsor
- CytoCares
- Start
- Sep 2025
- Primary completion
- Sep 2027
- Modality
- Antibody Conjugates, Trispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing CC312 with Placebo (2 arms). Primary endpoint: Adverse events (AE)/serious adverse events (SAE) at 2 years. Started Sep 2025; status: recruiting.
02
Drugs
CC312
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT07177911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07177911.